PMID- 27356906 OWN - NLM STAT- MEDLINE DCOM- 20170501 LR - 20170501 IS - 1097-0215 (Electronic) IS - 0020-7136 (Linking) VI - 139 IP - 9 DP - 2016 Nov 1 TI - Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia. PG - 2106-15 LID - 10.1002/ijc.30249 [doi] AB - Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective therapy for children with high-risk acute lymphoblastic leukemia (ALL). Human leukocyte antigen (HLA)-haploidentical HSCT (haplo-HSCT) or umbilical cord blood transplantation (UCBT) are both important alternative sources of stem cells for those without an HLA-identical sibling donor or unrelated matched donor. We aimed to compare the therapeutic effects of single UCBT and unmanipulated haplo-HSCT in high-risk ALL children (n = 129). Hematopoietic recovery was significantly faster in haplo-HSCT recipients than in UCBT recipients. The 2-year cumulative incidences of relapse in the haplo-HSCT and UCBT groups were 16.1% and 24.1%, respectively (p = 0.169). The 2-year cumulative incidences of non-relapse mortality in the haplo-HSCT and UCBT groups were 12.8% and 18.8%, respectively (p = 0.277). The 2-year probabilities of overall survival in the haplo-HSCT and UCBT groups were 82.0% and 69.6%, respectively (p = 0.071), and the 2-year probability of disease-free survival in the haplo-HSCT group was higher than in the UCBT group (71.0% vs. 57.2%, p = 0.040). However, several variables (such as leukocyte count and cytogenetics at diagnosis) were different between the groups, and a possible center effect should also be considered. In addition, only mild and moderate chronic graft-versus-host disease (GVHD) was associated with significantly improved survival compared to those without chronic GVHD in multivariate analysis. Thus, our results show that both unmanipulated haplo-HSCT and UCBT are valid for high-risk ALL children lacking a HLA matched donor, and both strategies expand the donor pool for children in need. CI - (c) 2016 UICC. FAU - Mo, Xiao-Dong AU - Mo XD AD - Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China. AD - Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. FAU - Tang, Bao-Lin AU - Tang BL AD - Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China. FAU - Zhang, Xiao-Hui AU - Zhang XH AD - Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China. AD - Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. FAU - Zheng, Chang-Cheng AU - Zheng CC AD - Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China. FAU - Xu, Lan-Ping AU - Xu LP AD - Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China. AD - Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. FAU - Zhu, Xiao-Yu AU - Zhu XY AD - Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China. FAU - Wang, Yu AU - Wang Y AD - Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China. AD - Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. FAU - Liu, Hui-Lan AU - Liu HL AD - Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China. FAU - Yan, Chen-Hua AU - Yan CH AD - Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China. AD - Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. FAU - Chu, Xian-Deng AU - Chu XD AD - Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China. FAU - Chen, Huan AU - Chen H AD - Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China. AD - Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. FAU - Geng, Liang-Quan AU - Geng LQ AD - Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China. FAU - Liu, Kai-Yan AU - Liu KY AD - Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China. AD - Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. FAU - Sun, Zi-Min AU - Sun ZM AD - Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, China. FAU - Huang, Xiao-Jun AU - Huang XJ AD - Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China. AD - Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. AD - Peking-Tsinghua Center for Life Sciences, Beijing, China. LA - eng PT - Comparative Study PT - Journal Article DEP - 20160715 PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 SB - IM MH - Adolescent MH - Child MH - Child, Preschool MH - Cord Blood Stem Cell Transplantation/*methods MH - Female MH - Graft vs Host Disease/*epidemiology MH - Hematopoietic Stem Cell Transplantation/*methods MH - Humans MH - Male MH - Neoplasm Recurrence, Local/*epidemiology MH - Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality/*therapy MH - Recurrence MH - Survival Analysis MH - Treatment Outcome OTO - NOTNLM OT - acute lymphoblastic leukemia OT - children OT - haploidentical OT - stem cell transplantation OT - umbilical cord blood transplantation EDAT- 2016/07/01 06:00 MHDA- 2017/05/02 06:00 CRDT- 2016/07/01 06:00 PHST- 2016/04/12 00:00 [received] PHST- 2016/06/21 00:00 [accepted] PHST- 2016/07/01 06:00 [entrez] PHST- 2016/07/01 06:00 [pubmed] PHST- 2017/05/02 06:00 [medline] AID - 10.1002/ijc.30249 [doi] PST - ppublish SO - Int J Cancer. 2016 Nov 1;139(9):2106-15. doi: 10.1002/ijc.30249. Epub 2016 Jul 15.